|Bid||1,975.50 x 0|
|Ask||1,978.00 x 0|
|Day's Range||1,942.50 - 1,978.00|
|52 Week Range||1,491.50 - 2,212.00|
|Beta (5Y Monthly)||0.20|
|PE Ratio (TTM)||13.28|
|Earnings Date||Feb 27, 2020|
|Forward Dividend & Yield||0.28 (1.44%)|
|Ex-Dividend Date||Aug 22, 2019|
|1y Target Est||23.92|
Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P;), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today's therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing today's therapies to enable healthier lives, today announce they have entered into an exclusive agreement to co-develop a new, ready-to-use injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
LONDON MARKETS British stocks slumped on Monday in a broad-based retreat on worries over Middle East tensions. The U.K. FTSE 100 (UK:UKX) weakened 0.78% to 7562.72, with decliners outnumbering advancers by a 1589-to-590 margin.
Dividend paying stocks like Hikma Pharmaceuticals PLC (LON:HIK) tend to be popular with investors, and for good reason...
Moody's Investors Service ("Moody's") has affirmed all the ratings of London-listed generic drug company Hikma Pharmaceuticals PLC ("Hikma"), comprising the Ba1 corporate family rating (CFR), the Ba1-PD probability of default rating (PDR) and Ba1 instrument rating on its existing senior unsecured bond. The affirmation of the Ba1 CFR is supported by the company's recent good performance against price pressures, in particular in the US, its good product pipeline of over 300 products across business segments and geographies, and strong credit metrics as a result of a conservative balance sheet structure. Since 2017, Hikma's sales volumes have been driven by some product differentiation and also benefitted from certain drug shortages in the US market (the region represents 66% of Hikma's revenue), as well as capacity expansion.
Civica Rx (Civica, Inc.) and Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P), the multinational generic pharmaceutical company, today announced imminent shipments of Heparin Sodium Injection, USP, and seven other essential injectable medicines, with additional products to follow in the near term in the US through its affiliate, Hikma Pharmaceuticals USA Inc.1
LONDON, Nov. 18, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) announces that its venture capital arm, Hikma Ventures has led a CAD 5.6 million oversubscribed round of financing for Winterlight Labs Inc. with participation from First Star Ventures, Pacific Health Ventures, existing investor Grey Sky Venture Partners and other investors. Toronto-based Winterlight Labs Inc. is developing a proprietary Artificial Intelligence (AI) technology that melds computational linguistics, cognitive neuroscience, and machine learning to help healthcare professionals assess and analyse patients' cognitive health – including memory, thinking and reasoning – from vocal markers captured in short snippets of speech on a tablet computer.
Does the November share price for Hikma Pharmaceuticals PLC (LON:HIK) reflect what it's really worth? Today, we will...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Hikma Pharmaceuticals PLC and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
Heparin Sodium Injection in a ready-to-use syringe is the first product using Hikma's new injectable manufacturing capability LONDON , Sept. 17, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
After Hikma Pharmaceuticals PLC's (LON:HIK) earnings announcement on 30 June 2019, analyst consensus outlook appear...
LONDON and SALT LAKE CITY, July 23, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational generic pharmaceutical company and Civica Rx (Civica, Inc.) today announce a five-year agreement to manufacture and supply Civica's growing membership of US health systems with medications that are often in short supply in US hospitals. Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica as a private label distributor, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's labeling and National Drug Code (NDC).
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
LONDON, May 30, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (HIK.L) (NASDAQ Dubai: HIK) (HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable) today announced its venture capital arm Hikma Ventures has participated in an $11 million financing round for Boston-based Pillo Health. The Series A round, led by Stanley Black & Decker's corporate venture capital arm with participation from Samsung Ventures and existing investors BioAdvance, Hackensack Meridian Health System's Innovation Center Fund and Civilization Ventures, will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for home use. "Our investment in Pillo Health underscores our deep commitment to developing innovative healthcare technology solutions that will put better health within reach for more patients around the world," said Lana Ghanem, Managing Director Hikma Ventures.
BOSTON, May 29, 2019 /PRNewswire/ -- Pillo Health, a Boston-based technology company improving longevity and quality of life for patients managing their health at home, today announced that is has secured $11 million in funding from leading venture investors to complete its Series-A round. The capital will be used to drive growth and innovation as Pillo Health builds out its voice-enabled medication and care management platform for the home.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Hikma Pharmaceuticals PLC (LON...
The Grand Hack is MIT Hacking Medicine's annual flagship event dedicated to energise, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide. More than 500 participants, mentors and sponsors from 25 US states and 29 countries are expected to gather on campus in the MIT Media Lab for this year's Grand Hack, the largest healthcare hackathon in the US. As a strategic sponsor, Hikma and its venture capital arm Hikma Ventures will support the Grand Hack's 'Personalised Medicine' theme, which focuses on solving challenges in improving preventative medicine, treatment affordability and personalised medicine dosages. Hikma will also have representatives on-site to speak with those attendees interested in exploring opportunities to join Hikma in its mission of putting better health within reach of millions of people through its high-quality medicines and healthcare solutions.
"Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio," said Dan Motto, Executive Vice President, Commercial and Development, Injectables.